Convictus Ukraine is a team of innovators, researchers and practitioners. For 17 years, their organisation has been a reliable partner of government agencies and non-governmental organizations in implementing programs to combat HIV, TB, hepatitis, and other socially significant diseases and creating sustainable models of providing accessible social and psychological services to vulnerable groups of the population. The organisation, with the support of the International Charitable Foundation Alliance for Public Health (funded by the Global Fund, CDC) implemented services for the diagnosis of HCV (B, C) as part of the organisation’s implementation of HIV, and HCV prevention programs among the most-at-risk populations.
The following activities were implemented:
HCV micro-elimination among key population groups (PLHIV and TB, co- and mono-HCV-infected PWID)
Component objectives: search and case management during the treatment of hepatitis C virus (hereinafter referred to as HCV) in patients of key populations (PLHIV and TB, co- and mono-HCV-infected PWID).
Target group: patients with HIV/HCV co-infection; PWID and their partners with mono-HCV infection, patients with TB/HCV co-infection from key populations – PWID.
Main activities under the program component:
1. Search and referral of clients for laboratory diagnostics to confirm the diagnosis of HCV infection, initiation of therapy and further management of HCV infection;
2. Support / monitoring of treatment progress and results;
3. Prevention of re-infection with HCV;
4. Control of treatment effectiveness (endpoint of therapy – laboratory diagnostics);
5. Reporting and maintaining a patient data registry.
Expected results of the implementation of the activity:
1. clients enrolled in treatment for hepatitis C virus (HCV); 2. patients who have completed the full course of HCV treatment; 3. patients on social support who have attended three sessions on the prevention of reinfection; 4. patients who have appeared for the final diagnostics to determine the effectiveness of treatment 12 weeks after its completion.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close